Correction: Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies

Fuling Ma; Liang Dai; Zhun Wang; Liqun Zhou; Yuanjie Niu; Ning Jiang

doi:10.18632/oncotarget.25726

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies

PDF | How to cite

Oncotarget. 2018; 9:29285-29285. https://doi.org/10.18632/oncotarget.25726

Metrics: PDF 1549 views | ?

Fuling Ma^1,*, Liang Dai^1,*, Zhun Wang^1,*, Liqun Zhou², Yuanjie Niu¹ and Ning Jiang¹

¹Department of Urology, 2nd Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
²Department of Urology, Peking University First Hospital, The Institute of Urology, Peking University, Beijing 100034, China
^*These authors have contributed equally to this work

Published: June 26, 2018

This article has been corrected: The complete funding information is given below:

FUNDING

The project was supported by a research grant of National Basic Research Program of China (973 Program, 2012CB518304). and the Science Foundation of Tianjin (No.: 11JCZDJC19700, 16JCZDJC34400) and 09ZCZDSF04300, 14KG135, 20140117 and the National Natural Science Foundation of China Grant numbers: 2012DFG32220 and 81572538, 81472682. Ph.D Programs Foundation of Ministry of Education of China 20131202110008.

Original article: 2016; 7:46528-46535. DOI: https://doi.org/10.18632/oncotarget.10225.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25726

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies